Understand the source comparison
Best Peptides for Chronic Sinusitis: Efficacy Comparison
BPC-157 VEGF upregulation, tight junction repair, angiogenesis Intranasal spray (250–500 mcg/mL) or SC injection Mucosal healing visible 7–14 days; symptom improvement 3–6 weeks Preclinical animal models, case reports Strongest evidence for direct epithelial r
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, tight junction repair, angiogenesis
- Intranasal spray (250–500 mcg/mL) or SC injection
- Mucosal healing visible 7–14 days; symptom improvement 3–6 weeks
- Preclinical animal models, case reports
- Strongest evidence for direct epithelial repair. Ideal for post-surgical healing or barrier dysfunction
- Thymosin Alpha-1
- T-cell modulation, Th1/Th2 balance restoration, reduces eosinophilic inflammation
- Subcutaneous injection (1.6 mg 2×/week)
- Immune shift detectable 4–6 weeks; polyp reduction 8–12 weeks
- Phase 2 human trial (chronic rhinosinusitis with polyps)
- Best for immune-driven chronic sinusitis. Not acute infection
- KPV Tripeptide
- NF-κB inhibition, blocks inflammatory gene transcription
- Intranasal or sublingual
- Anti-inflammatory effect 48–72 hours; sustained benefit requires daily dosing
- Colitis models, extrapolated to nasal mucosa
- Rapid symptom relief but requires consistent administration
- Thymalin
- Thymic peptide complex, immune system normalisation
- Intramuscular or subcutaneous injection
- Gradual immune restoration over 4–8 weeks
- Limited human data, primarily Soviet-era research
- Broader immune support rather than sinus-specific targeting
- LL-37 (Cathelicidin)
- Antimicrobial peptide, biofilm disruption
- Intranasal (experimental only)
- Biofilm reduction 3–5 days in vitro
- In vitro biofilm studies, no controlled human trials
- Promising for biofilm-associated sinusitis but delivery challenges remain